BIOMAT Database Logo BIOMAT Database Logo

Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. 1988

J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Department of Onco-Hematology, University Hospital, Strasbourg, France.

Among 40 evaluable patients with metastatic renal cell cancer treated by high-dose interferon alpha-2a in combination with vinblastine, the authors have observed a 42.5% response rate. The 8 months' median duration of remissions is relatively short but some patients experience very long remissions, lasting many months after discontinuation of therapy. The survival of responding patients is significantly longer than the survival of nonresponders. The diverging results of other studies of the same combination are discussed; its efficacy is certainly dependent on the type of interferon, on the dose actually administered, and on the compliance to this often poorly tolerated treatment.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
[Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer].
October 1990, Onkologie,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine.
December 1991, Journal of chemotherapy (Florence, Italy),
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.
August 1989, The Journal of urology,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
August 1990, Journal of biological response modifiers,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.
February 1989, American journal of clinical oncology,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
[Treatment of metastatic renal adenocarcinomas with combined recombinant alpha-2a interferon and vinblastine].
November 1987, Presse medicale (Paris, France : 1983),
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
[Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
January 1993, Wiener klinische Wochenschrift,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.
September 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma.
April 1986, Cancer,
J P Bergerat, and R Herbrecht, and P Dufour, and D Jacqmin, and C Bollack, and G Prevot, and G Bailly, and S de Garis, and F Juraschek, and F Oberling
Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial.
January 1990, Acta oncologica (Stockholm, Sweden),
Copied contents to your clipboard!